SRPT - Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 | Benzinga
Needham analyst forecasts a positive outlook for Arcellx Inc (NASDAQ:ACLX) in 2024, citing strong potential stemming from the anticipated pivotal interim readout from the iMMagine-1 study, expected in the second half of 2024.
This development is poised to bolster filing prospects for the company in 2025. CART-ddBCMA (anitocabtagene autoleucel or anito-cel), the flagship product of Arcellx, displays promising potential for value creation, particularly upon disclosing its clinical design for deployment in earlier line settings.
Needham analyst reiterates a ...